{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:15:38Z","timestamp":1792160138846,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2018.04.065","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T09:19:28Z","timestamp":1524734368000},"page":"4601-4609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes"],"prefix":"10.1016","volume":"37","author":[{"given":"Valerie","family":"Lecouturier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aure","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Naville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Manin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Girerd-Chambaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.04.065_b0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.04.065_b0010","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.04.065_b0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.04.065_b0020","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.04.065_b0025","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.04.065_b0030","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.04.065_b0035","doi-asserted-by":"crossref","first-page":"e00873","DOI":"10.1128\/mBio.00873-13","article-title":"The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein","volume":"4","author":"Smith","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2018.04.065_b0040","doi-asserted-by":"crossref","first-page":"12233","DOI":"10.1128\/JVI.00247-14","article-title":"Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones","volume":"88","author":"Smith","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.065_b0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2018.04.065_b0050","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1038\/ncomms7341","article-title":"A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins","volume":"6","author":"Fibriansah","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.04.065_b0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.04.065_b0060","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward","volume":"33","author":"Guy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.065_b0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-med-091014-090848","article-title":"Vaccination against dengue: challenges and current developments","volume":"67","author":"Guy","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2018.04.065_b0070","doi-asserted-by":"crossref","first-page":"e0004821","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials","volume":"10","author":"Gailhardou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.04.065_b0075","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1016\/j.vaccine.2015.08.008","article-title":"Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study","volume":"33","author":"Torresi","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2018.04.065_b0080","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1016\/j.vaccine.2013.10.013","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2\u201311 years in Malaysia: a randomized, placebo-controlled, Phase III study","volume":"31","author":"Hss","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.065_b0085","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1126\/science.1153264","article-title":"Structure of the immature dengue virus at low pH primes proteolytic maturation","volume":"319","author":"Yu","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.04.065_b0090","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.04.065_b0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2018.04.065_b0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jviromet.2008.03.026","article-title":"Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines","volume":"151","author":"Mantel","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.04.065_b0105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.04.065_b0110","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1128\/JVI.00757-13","article-title":"Structural changes in dengue virus when exposed to a temperature of 37 degrees C","volume":"87","author":"Fibriansah","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.065_b0115","doi-asserted-by":"crossref","first-page":"e2451","DOI":"10.1371\/journal.pntd.0002451","article-title":"Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases","volume":"7","author":"Lai","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.04.065_b0120","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1128\/JVI.00871-13","article-title":"High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection","volume":"87","author":"Tsai","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.065_b0125","doi-asserted-by":"crossref","unstructured":"Rabaa MA, Girerd-Chambaz Y, Duong KTH, Vu TT Wills B, Bonaparte M, van der Vliet D, et al. Genetic epidemiology of dengue virus in phase III trials of the CYD tetravalent vaccine and implications for efficacy. eLife 2017;6:exxxxx","DOI":"10.7554\/eLife.24196"},{"key":"10.1016\/j.vaccine.2018.04.065_b0130","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in na\u00efve and dengue- exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.065_b0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2018.04.065_b0140","doi-asserted-by":"crossref","first-page":"e1006934","DOI":"10.1371\/journal.ppat.1006934","article-title":"Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes","volume":"14","author":"Gallichotte","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.04.065_b0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.04.065_b0150","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1016\/j.vaccine.2016.08.050","article-title":"Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine","volume":"34","author":"Coudeville","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.065_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","author":"Arredondo-Garc\u00eda","year":"2018","journal-title":"Clinical Microbiol Infect"},{"key":"10.1016\/j.vaccine.2018.04.065_b0160","doi-asserted-by":"crossref","unstructured":"Byers AM, Broder R, Haupfear K, Timiryasova TM, Hu BT, Boaz M et al. Influence of Fc\u03b3RIIa-expressing cells on the assessment of neutralizing and enhancing serum antibodies elicited by a live-attenuated tetravalent dengue vaccine. Open Forum Infect Dis. 2015;2:ofv172","DOI":"10.1093\/ofid\/ofv172"},{"issue":"7","key":"10.1016\/j.vaccine.2018.04.065_b0165","doi-asserted-by":"crossref","first-page":"e0004830","DOI":"10.1371\/journal.pntd.0004830","article-title":"Cytokine profile of children hospitalized with virologically-confirmed dengue during two phase III vaccine efficacy trials","volume":"10","author":"Harenberg","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.04.065_b0170","doi-asserted-by":"crossref","first-page":"8909","DOI":"10.1128\/JVI.00472-13","article-title":"Obstruction of dengue virus maturation by Fab fragments of the 2H2 antibody","volume":"87","author":"Wang","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.065_b0175","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4269\/ajtmh.1982.31.548","article-title":"Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies","volume":"31","author":"Gentry","year":"1982","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.04.065_b0180","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(02)00660-8","article-title":"Structure of dengue virus: implications for flavivirus organization, maturation, and fusion","volume":"108","author":"Kuhn","year":"2002","journal-title":"Cell"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T23:34:57Z","timestamp":1571268897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":36,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X18305620"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}